IntraEpiGlioma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00027365

Enrollment

200

Registered

2023-10-17

Start date

2020-03-05

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C71

Interventions

Group 1: Patient samples of suspected glioma or brain metastasis are molecularly examined during surgery.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Suspected primary brain tumor or brain metastasis

Exclusion criteria

Exclusion criteria: Other tumor entities

Design outcomes

Primary

Measure	Time frame
100 samples from different patients will be included to enable a valid assessment of the new diagnostic method. The number of patients should be reached around the end of 2023. The aim should be to obtain a valid molecular diagnosis during ongoing surgery.	—

Secondary

Measure	Time frame
Recruiting till 2023	—

Countries

Germany

Contacts

Public ContactCarolin Kubelt

Klinik für Neurochirurgie am UKSH, Campus Kiel

carolin.kubelt@uksh.de+4943150069614

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026